

Executive	As Passed By House	As Reported By Senate Finance
PRXCD2 OARRS access R.C. 3796.32 Requires PRX to allow COM's Division of Marijuana Control, which is created by the bill, to access the Ohio Automated Rx Reporting System (OARRS) as needed to ensure compliance with the Medical Marijuana Control Program Law.	R.C. 3796.32 Same as the Executive.	No provision; see COMCD18.
Fiscal effect: Minimal cost.	Fiscal effect: Same as the Executive.	
PRXCD3 Administration of immunizations by pharmacists, pharmacy interns, and pharmacy technicians No provision.	No provision.	R.C. 4729.41 Authorizes certified pharmacy technicians and registered pharmacy technicians to administer immunizations in the same manner as pharmacy interns under current law.
No provision.	No provision.	Authorizes pharmacists, interns, and technicians to administer immunizations beginning when a child is age 5, as opposed to the current law age limit of 7.
No provision.	No provision.	Eliminates, for children under age 13, a requirement that their immunizations be prescribed (immunizations for COVID-19 and the flu do not require a prescription under current law or the amendment).
No provision.	No provision.	Requires, for each immunization administered to a child under age 18, that the pharmacist, intern, or technician inform the child's parent or legal guardian of the importance of well child visits with a pediatrician or other primary care provider, and refer patients when appropriate.
		Fiscal effect: Potential minimal annual increase in PRX compliance inspection and enforcement costs.

Executive

As Passed By House

As Reported By Senate Finance

PRXCD4 Terminal distributor license exemptions

No provision.

No provision.

R.C. 4729.541, conforming changes in R.C. 4729.51,
4729.55

Adds the following exemptions from licensure as a terminal distributor of dangerous drugs: (1) a person who possesses nitrous oxide for use as a direct ingredient in food under federal regulations or for testing or maintaining a plumbing or HVAC system; (2) a person who possesses medical oxygen, sterile water, or sterile saline for direct patient administration or for installing or maintaining home medical equipment; and (3) a person who possesses controlled substances and other dangerous drugs for dog training in conjunction with a law enforcement agency.

Fiscal effect: Potential loss in license fee and civil penalty revenue credited to the Occupational Licensing and Regulatory Fund (Fund 4K90) and related decrease in PRX administrative costs as there may be fewer distributors licensed and regulated.

PRXCD5 Repeal of office-based opioid treatment (OBOT) licensure

No provision.

No provision.

R.C. 4729.553, (Repealed), conforming changes in numerous other R.C. sections and Section 747.30

Eliminates PRX's licensure of terminal distributors of dangerous drugs with an office-based opioid treatment (OBOT) classification, which is required for facilities, clinics, and other locations providing OBOT to more than 30 patients.

Fiscal effect: Loss in license fee and civil penalty revenue credited to the Occupational Licensing and Regulatory Fund (Fund 4K90) and related decrease in PRX administrative costs as there will be fewer distributors licensed and regulated.

Executive

As Passed By House

As Reported By Senate Finance

PRXCD1 Cash transfer from the Medical Marijuana Control Program Fund to the Drug Database Fund**Section: 367.10**

Permits the COM Director, upon request of the PRX Director, to certify an amount needed for the operation of PRX's drug database in each fiscal year. Permits the transfer of that amount from the Medical Marijuana Control Program Fund (Fund 5YS0), used by COM, to the Drug Database Fund (Fund 5SG0), used by PRX.

Section: 367.10

Same as the Executive.

Section: 367.10

Replaces the Executive provision with a provision that permits the PRX Director, in each fiscal year, to certify to the OBM Director an amount in cash to be transferred from Fund 5SY0 to Fund 5SG0, and upon Controlling Board approval, appropriates any transferred amounts. Makes technical correction to reference "Fund 5SY0" instead of "Fund 5YS0".

Executive

As Passed By House

As Reported By Senate Finance

COMCD18 Division of Marijuana Control and transfer of Medical Marijuana Control Program

R.C. **121.08, 121.04, 3796.02, 3796.03, 3796.032, 3796.04 (repealed), 3796.05, 3796.06, 3796.061, 3796.08, 3796.10, 3796.11, 3796.12, 3796.13, 3796.14, 3796.15, 3796.16, 3796.17, 3796.19, 3796.20, 3796.22, 3796.23, 3796.27, 3796.30, 4776.01; Section 525.20; Conforming changes in R.C. 109.572, 1321.37, 1321.53, 1321.64, 4735.143, 4763.05, 4764.06, 4764.07, 4768.03, 4768.06**

R.C. **121.08, 121.04, 3796.02, 3796.03, 3796.032, 3796.04 (repealed), 3796.05, 3796.06, 3796.061, 3796.08, 3796.10, 3796.11, 3796.12, 3796.13, 3796.14, 3796.15, 3796.16, 3796.17, 3796.19, 3796.20, 3796.22, 3796.23, 3796.27, 3796.30, 4776.01; Section 525.20; Conforming changes in R.C. 109.572, 1321.37, 1321.53, 1321.64, 4735.143, 4763.05, 4764.06, 4764.07, 4768.03, 4768.06**

R.C. **121.08, 121.04, 3796.02, 3796.03, 3796.032, 3796.04 (repealed), 3796.05, 3796.06, 3796.061, 3796.08, 3796.10, 3796.11, 3796.12, 3796.13, 3796.14, 3796.15, 3796.16, 3796.17, 3796.19, 3796.20, 3796.22, 3796.23, 3796.27, 3796.30, 4729.80, 4729.86, 4776.01; Section 525.20; Conforming changes in R.C. 109.572, 1321.37, 1321.53, 1321.64, 4735.143, 4763.05, 4764.06, 4764.07, 4768.03, 4768.06**

Creates the Division of Marijuana Control (DMC) within COM and requires PRX and COM to transfer the Medical Marijuana Control Program (MMCP) to DMC no later than December 31, 2023.

Same as the Executive.

Same as the Executive.

Establishes a Superintendent of Marijuana Control to oversee DMC.

Same as the Executive.

Same as the Executive.

Specifies that licenses and registrations issued by COM and PRX remain in effect for the remainder of their term and that forms of medical marijuana approved by PRX remain approved unless that approval is later revoked by DMC.

Same as the Executive.

Same as the Executive.

Specifies that COM and PRX rules related to MMCP remain in effect until repealed or amended by DMC, but requires DMC to review and propose revisions to existing rules on retail dispensaries no later than March 1, 2024.

Same as the Executive.

Same as the Executive.

Allows DMC to investigate alleged violations of the Medical Marijuana Law, including by subpoenaing documents and witnesses.

Same as the Executive.

Same as the Executive.

Requires PRX to grant DMC access to the Ohio Automated Rx Reporting System (OARRS) as needed to ensure compliance with the Medical Marijuana Law.

Same as the Executive.

Replaces the Executive provision with one that requires PRX, on receipt of a request from a designated representative of DMC, to provide to the representative information from OARRS relating to an individual who, or entity that, is the subject of an active investigation being conducted by DMC.

Executive**As Passed By House****As Reported By Senate Finance**

Makes conforming changes throughout the Revised Code.

Same as the Executive.

Same as the Executive.

Fiscal effect: Increases costs for COM for overseeing PRX's portion of MMCP, and simultaneously reduces costs for PRX. The executive provides funding for these purpose under Fund 5SY0 ALI 800650, Medical Marijuana Control Program.

Fiscal effect: Same as the Executive.

Fiscal effect: Same as the Executive.

Executive

As Passed By House

As Reported By Senate Finance

MEDCD2 Legacy pain management study committee

No provision.

Section: 335.20

Establishes the Legacy Pain Management Study Committee to study and evaluate the care and treatment of patients suffering from chronic or debilitating pain, in particular those who have been prescribed opioids for lengthy periods of time, often referred to as legacy patients.

No provision.

Includes the following as members of the committee: four members of the General Assembly, one representative of OhioMHAS, one representative of SMBO, one representative of PRX, one member representing patients, and one member representing prescribers.

No provision.

Requires the committee to consider several topics relating to legacy patients, including the availability of and access to pain management specialists in Ohio and the challenges associated with tapering opioid doses.

No provision.

Requires the committee, by December 1, 2024, to prepare and submit to the General Assembly a report of its recommendations for legislation to address the care and treatment of legacy patients.

Fiscal effect: Minimal.**Section: 335.20**

Same as the House.

Same as the House.

Same as the House.

Same as the House.

Fiscal effect: Same as the House.

Executive**As Passed By House****As Reported By Senate Finance****MHACD21 Mobile-based opioid use disorder treatment****Section: 337.95**

Requires OhioMHAS to operate a pilot program during FY 2024 and FY 2025 to provide opioid use disorder treatment to individuals in underserved regions selected by OhioMHAS, using medication units that are mobile.

Specifies that the purpose of the program is to extend access to medication-assisted treatment to areas of the state lacking licensed opioid treatment programs and qualifying practitioners.

Requires OhioMHAS to ensure that the services provided in mobile medication units used in the pilot program are those specified in relevant guidance issued by the U.S. Substance Abuse and Mental Health Services Administration.

Requires PRX, SMBO, and NUR and any other state agency that OhioMHAS determines may be of assistance in accomplishing the pilot program's purpose to provide assistance upon request from OhioMHAS.

Requires OhioMHAS to develop a plan for implementing and evaluating the pilot program within 60 days of the section's effective date.

Requires OhioMHAS to complete a report of the findings obtained from the program within six months after the conclusion of the pilot program.

Earmarks \$750,000 in each fiscal year in GRF ALI 336504, Community Innovations, to operate the pilot program.

Section: 337.95

Same as the Executive.

No provision.

Same as the Executive.

No provision.